Philip Toleikis, Ph.D., President and CEO

Oct. 11 | 5:30pm | Aseptic Technologies Ballroom 

London, Ontario


Sernova Corp is a clinical-stage biotechnology company developing therapeutic cell technologies with a goal to deliver a ‘functional cure’ for chronic diseases, including insulin-dependent diabetes, thyroid disease and hemophilia A. Sernova has developed the Cell Pouch System™, an implantable, scalable, and retrievable medical device which forms a natural environment for long-term survival and function of immune-protected therapeutic cells. In Sernova’s T1D clinical program, the first three patients to complete the trial protocol have achieved insulin independence. A second patient cohort has now been initiated with interim results expected in June 2023. In 2022, Sernova and Evotec (NASDAQ: EVO) entered into a partnership to develop an off-the-shelf iPSC based islet replacement therapy for potentially millions of patients with diabetes which will enter the clinic in 2024. Sernova has licensed a technology from the University of Miami to cloak cells, potentially eliminating the need for immunosuppressives to protect against immune system attack.

By using this website you agree to accept our Privacy Policy and Terms & Conditions